NTRK, ROS1, and ALK Fusions in Gynecological Tumors
Gynecological tumors include ovarian cancer, uterine cancer, and other cancers affecting any part of a woman's reproductive organs. The National Cancer Institute estimates that over 80,000 women in America will be diagnosed with a gynecological tumor in 2016.
More research is needed on the underlying causes of tumors in the female reproductive system. Ignyta is conducting research to better understand the occurrence of NTRK, ROS1, and ALK gene fusions in gynecological tumors. By studying these genes in large groups of people, we measured the proportion of tumors that carry rearrangements that might be treatable with entrectinib.
The STARTRK-2 clinical trial may be an option for patients with late stage or metastatic gynecologic tumors with NTRK, ROS1, or ALK fusions.
See if you or a loved one may be eligible for the study.